First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus
- PMID: 33268959
- PMCID: PMC7684461
- DOI: 10.3748/wjg.v26.i43.6710
First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus
Abstract
Ulcerative colitis and Crohn's disease are the main entities of inflammatory bowel disease characterized by chronic remittent inflammation of the gastrointestinal tract. The incidence and prevalence are on the rise worldwide, and the heterogeneity between patients and within individuals over time is striking. The progressive advance in our understanding of the etiopathogenesis coupled with an unprecedented increase in therapeutic options have changed the management towards evidence-based interventions by clinicians with patients. This guideline was stimulated and supported by the Emirates Gastroenterology and Hepatology Society following a systematic review and a Delphi consensus process that provided evidence- and expert opinion-based recommendations. Comprehensive up-to-date guidance is provided regarding diagnosis, evaluation of disease severity, appropriate and timely use of different investigations, choice of appropriate therapy for induction and remission phase according to disease severity, and management of main complications.
Keywords: Adalimumab; Crohn’s disease; Infliximab; Tofacitinib; Ulcerative colitis; Ustekinumab; Vedolizumab.
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Similar articles
-
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.Gut. 2019 Dec;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. Epub 2019 Sep 27. Gut. 2019. PMID: 31562236 Free PMC article. Review.
-
Inflammatory Bowel Disease: A Concise Review.S D Med. 2023 Sep;76(9):416-423. S D Med. 2023. PMID: 37738497 Review.
-
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.BMC Gastroenterol. 2022 Jun 8;22(1):291. doi: 10.1186/s12876-022-02347-1. BMC Gastroenterol. 2022. PMID: 35676620 Free PMC article.
-
Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus.Endoscopy. 2009 Jul;41(7):618-37. doi: 10.1055/s-0029-1214790. Epub 2009 Jul 8. Endoscopy. 2009. PMID: 19588292 Review.
-
[Inflammatory bowel disease: an overview].Med Monatsschr Pharm. 2013 Nov;36(11):402-8; quiz 409. Med Monatsschr Pharm. 2013. PMID: 24640117 Review. German.
Cited by
-
Efficacy and Safety of Infliximab Versus Adalimumab in Adult Subjects With Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis.Cureus. 2024 Jun 2;16(6):e61547. doi: 10.7759/cureus.61547. eCollection 2024 Jun. Cureus. 2024. PMID: 38835557 Free PMC article. Review.
-
Unraveling the Impact of Gut and Oral Microbiome on Gut Health in Inflammatory Bowel Diseases.Nutrients. 2023 Jul 29;15(15):3377. doi: 10.3390/nu15153377. Nutrients. 2023. PMID: 37571313 Free PMC article. Review.
-
Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease.BMC Gastroenterol. 2021 Aug 3;21(1):312. doi: 10.1186/s12876-021-01883-6. BMC Gastroenterol. 2021. PMID: 34344314 Free PMC article.
-
Predicting Mucosal Healing in Crohn's Disease: A Nomogram Model Developed from a Retrospective Cohort.J Inflamm Res. 2022 Sep 23;15:5515-5525. doi: 10.2147/JIR.S378304. eCollection 2022. J Inflamm Res. 2022. PMID: 36176354 Free PMC article.
-
Combination of serological biomarkers and clinical features to predict mucosal healing in Crohn's disease: a multicenter cohort study.BMC Gastroenterol. 2022 May 10;22(1):229. doi: 10.1186/s12876-022-02304-y. BMC Gastroenterol. 2022. PMID: 35538410 Free PMC article.
References
-
- Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010;105:289–297. - PubMed
-
- Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–1794. - PubMed
-
- Burisch J, Kiudelis G, Kupcinskas L, Kievit HAL, Andersen KW, Andersen V, Salupere R, Pedersen N, Kjeldsen J, D'Incà R, Valpiani D, Schwartz D, Odes S, Olsen J, Nielsen KR, Vegh Z, Lakatos PL, Toca A, Turcan S, Katsanos KH, Christodoulou DK, Fumery M, Gower-Rousseau C, Zammit SC, Ellul P, Eriksson C, Halfvarson J, Magro FJ, Duricova D, Bortlik M, Fernandez A, Hernández V, Myers S, Sebastian S, Oksanen P, Collin P, Goldis A, Misra R, Arebi N, Kaimakliotis IP, Nikuina I, Belousova E, Brinar M, Cukovic-Cavka S, Langholz E, Munkholm P Epi-IBD group. Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut. 2019;68:423–433. - PubMed
-
- Torres J, Billioud V, Sachar DB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis. 2012;18:1356–1363. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical